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Background: Numerous studies have investigated the association between hormone receptor
expression and clinical outcome in ovarian carcinoma (OC); however, these have largely focussed on
serous OCs, with few studies reporting speciﬁcally on endometrioid OCs (EnOC). Where analyses have
been stratiﬁed by histotype, expression has been assessed using the percentage of positive tumor cells,
without accounting for nuclear expression intensity.
Methods: Here we assess the expression levels of progesterone receptor (PR), estrogen receptor alpha
(ER) and androgen receptor (AR) using histoscore e a nuclear scoring method incorporating both pro-
portion of positive cells and the intensity of nuclear staining e across a cohort of 107 WT1 negative EnOCs.
Results: Hierarchical clustering by PR, ER and AR histoscores identiﬁed four EnOC subgroups (PRþ/
ERþ, PRþ/ER, PR/ERþ and PR/ER). EnOC patients in the PRþ/ERþ and PRþ/ER groups displayed
favorable outcome (multivariable HR for disease-speciﬁc survival 0.05 [0.01e0.35] and 0.05 [0.00e0.51])
compared to the PR/ERþ group. Ten-year survival for stage II PRhigh and PRlow cases was 94.1% and
42.4%. ERhigh EnOC patients (PRþ/ERþ, PR/ERþ) had higher body mass index compared to ERlow cases
(P¼ 0.015) and high grade serous OC patients (P < 0.001).
Conclusion: These data demonstrate that endometrioid OC cases with high PR expression display
markedly favorable outcome. Stage II EnOCs with high PR expression represent potential candidates for
de-escalation of ﬁrst-line therapy. Future work should seek to characterise the sensitivity of PR and ER
positive EnOCs to endocrine therapy.
© 2019 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction The vast majority of cases are ovarian carcinomas (OCs), comprisingOvarian cancer is the most lethal cancer of the female genital
tract, and accounts for over 180,000 deaths per year worldwide [1].varian Cancer Research, Level
te of Genetics and Molecular
dinburgh EH4 2XU, UK.
r Inc. This is an open access articleﬁve core histological subtypes: high grade serous (HGS), endome-
trioid, clear cell, low grade serous (LGS) and mucinous OC [2].
Endometrioid OCs (EnOCs) account for approximately 10% of
cases, are associated with favorable prognosis compared to other
histotypes, and are often diagnosed at FIGO stage I or II [2e4].
EnOCs are frequently estrogen receptor alpha (ER) and/or proges-
terone receptor (PR)-positive, and display WT1 negativity [5]. The
routine use of WT1 immunohistochemistry (IHC) is known tounder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Table 1
Demographics of 107 WT1 negative EnOCs.
N %/range
Age at diagnosis Median years 57 28e88
Body mass index Median 25.5 18.0e44.0
Disease grade G1 EnOC 80 74.7
G2 EnOC 19 17.8
G3 EnOC 8 7.5
FIGO stage at diagnosis I 47 44.8
II 42 40.0
III 10 9.5
IV 6 5.7
NA 2
RD following debulking <2 cma 93 90.3
2 cm 10 9.7
NA 4
p53 IHC pattern AP 11 10.5
AN 0 0.0
WT 94 89.5
NE 2
EnOC, endometrioid ovarian carcinoma; NA, not available; RD, residual disease; IHC,
immunohistochemistry; AP, aberrant diffuse nuclear positive; AN, aberrant null;
WT, wild-type; NE, not evaluable.
a Due to the retrospective nature of this cohort and the historic classiﬁcation of
<2 cm residual disease as optimal debulking, debulking status is not resolved
beyond <2 cm in this cohort.
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tion of these cases from HGS or LGS OCs which can demonstrate
morphological resemblance to EnOC [6,7].
Reports of the prognostic impact of hormone receptor expres-
sion in OC have largely focussed on serous cases, with studies
almost ubiquitously focusing on either these tumors alone [8e11],
or mixed patient populations dominated by OCs of serous histology
[12e17]. Mixed histology studies interrogating survival without
stratifying by histological subtype have the potential to be
confounded by the known differential expression of hormone re-
ceptors across these subtypes [6,18], which are now recognised to
demonstrate markedly distinct clinical outcome [3,4].
A number of studies have included EnOC cases when investi-
gating the prognostic impact of hormone receptor positivity on OC
outcome [13e16,19e22]; however, the majority of these studies
have included fewer than 30 EnOC cases in the context of mixed
histology cohorts [14e16,19,20]. One study collected a relatively
large series of EnOCs (84 cases), but did not perform histotype-
speciﬁc analysis of outcome [13]. The Ovarian Tumor Tissue Anal-
ysis Consortium investigated the prognostic impact of ER and PR
expression speciﬁcally in EnOC, where investigators used a three-
tier taxonomy for quantifying expression magnitude, reporting a
survival beneﬁt in ER-positive and PR-positive cases [21], which
was mirrored in an independent study of from Rambau et al. [22].
However, as with many other investigations of hormone receptor
expression in OC, these studies deﬁned positivity by the proportion
of marker-positive tumor cells (as <1%, 1e50% and 50% positive
tumor nuclei) without accounting for intensity of nuclear staining.
Quantiﬁcation of both the proportion of positive cells and the in-
tensity of nuclear expression may allow for a more granular
assessment of expression patterns. Notably, the most widely used
scoring systems for hormone receptor positivity incorporate both
of these measures [23].
Androgen receptor (AR) expression has also been associated with
favorableoutcome insomeOCcohorts [11,14,17];however, theclinical
impact of AR expression speciﬁcally in EnOC is poorly deﬁned.
Histoscore is a nuclear staining intensity scoring method which
incorporates both the proportion of positive tumor nuclei and the
intensity of nuclear staining [24]. We and others have demon-
strated the utility of ER histoscore for identifying OCs that derive
the greatest beneﬁt from endocrine therapy, and this method is
routinely used to identify good candidates for endocrine treatment
regimens locally within our centre [25e27].
Here we report on hormone receptor expression across a cohort
of EnOCs identiﬁed following contemporary pathology review
utilizing immunohistochemistry (IHC) for WT1. We quantify
expression of ER, PR and AR using histoscore in order to determine
the prognostic impact of hormone receptor expression patterns
speciﬁcally in EnOC.
2. Materials and methods
2.1. Cohort collection
We recently identiﬁed a cohort of 107 WT1 negative EnOCs
following contemporary pathology review of OC cases (n¼ 289)
with documented endometrioid histology from the Edinburgh
Ovarian Cancer Database (full data to be reported elsewhere). Tu-
mor material was reviewed using H&E stained slides and IHC with
antibodies for WT1 (DAKO, clone 6F-H2; 1:1000 dilution) and p53
(DAKO, clone DO-7; 1:50 dilution); metastases from primary uter-
ine carcinomas, as deﬁned by clinicopathological criteria [28], were
excluded. Use of human tumor tissue for research was approved by
South East Scotland Human Annotated BioResource (Lothian NRS
Bioresource ethics reference 15/ES/0094-SR494). Demographics of
the 107 WT1 negative EnOCs are summarised in Table 1.2.2. Clinical annotation
Correlation of molecular data to clinicopathological variables
and clinical outcome in patients with ovarian carcinoma was
approved by NHS Lothian Research and Development (reference
2007/W/ON/29). Clinical data were retrieved from the Edinburgh
Ovarian Cancer Database, wherein data regarding the diagnosis and
management of ovarian cancer patients treated at the Edinburgh
Cancer Centre are entered prospectively as part of routine care,
alongside archived patient records. Body mass index (BMI) was
calculated using patient height and weight as recorded at time of
ﬁrst chemotherapy administration. Adjuvant treatment regimens
and staging information is summarised in Table S1. Patients un-
derwent 3-monthly clinical follow-up for 2 years and 6-monthly
follow-up for a further 3 years, after which patients were tracked
via yearly contact with their general practitioner to determine
patient status. Radiological imaging was used to determine relapse
upon a signiﬁcant rise in CA125 or if patients presented with
symptomatic deterioration.
2.3. Immunohistochemical staining for PR, ER and AR
A human tissue microarray (TMA) was constructed to assess
tumor cell positivity for markers of interest. TMAs were con-
structed using H&E stained slides, marked to identify tumor area by
an expert pathologist (CSH), to guide tissue coring. Three 0.8mm
tissue cores were taken per EnOC case.
IHC for PR was performed using 1:50 mouse anti-human PR anti-
bodyM3569 (DAKO, clone PgR-636). ER stainingwas performed using
1:50 dilution of rabbit anti-human ER antibody M3643 (DAKO, clone
EP1). AR staining was performed using 1:50 dilution of mouse anti-
human AR antibody M3562 (DAKO, clone AR441). IHC was per-
formed using the Leica BOND III Autostainer with epitope retrieval
solution 2 for 20min. Normal human breast tissue was used as a
positivecontrol forERandPR,whilenormalhumanprostate tissuewas
used as a positive control for AR. Negative controls were performed
using further sections without the addition of primary antibody.
2.4. Histoscoring of PR, ER and AR immunohistochemical staining
Marker positivity was evaluated by histoscore, a nuclear stain-
ing scoring method incorporating both proportion of positive cells
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cells in each samples scored as 0 (negative), 1þ (weak positive), 2þ
(moderately positive), or 3þ (strong positive) was recorded, using
validated breast carcinoma control samples for comparison. Per-
core histoscore was calculated as 1(%cells 1þ)þ 2(%cells
2þ)þ 3(%cells 3þ) (Fig. S1).
Each core was scored by two independent observers. Compari-
son of histoscore assessment between the two observers demon-
strated excellent agreement (weighted Kappa >0.90 for all
markers; Spearman's r 0.85, P< 0.001) (Table S2).
Per-patient histoscore was calculated as the mean of evaluable
cores, weighted by percentage tumor present in each core (see
Appendix A). Cores with <10% tumor cellularity were excluded
from analysis. Patients with fewer than two assessable cores were
considered non-evaluable for marker expression.
2.5. Statistical analysis
Statistical analyses were performed using R version 3.5.1.
Relapse-free survival (RFS) was calculated as time from diagnosis to
ﬁrst radiological relapse. Comparisons of frequency were made us-
ing the Fisher's exact test and Chi-squared test, as appropriate. Data
modality and normality was assessed by Hartigan's Dip test and the
Shapiro-Wilk test. Comparisons of continuous variables were made
using the unpaired t-test and MannWhitney-U test, as appropriate.
Survival differences were assessed in the survival R package [29]
using Cox proportional hazards regression models and visualised
using the Kaplan-Meier method. Subgroups of EnOC were identiﬁed
byhierarchical clustering of PR, ER andARhistoscores using Euclidian
distanceandWard's Linkage. Correction formultiplicityof testingwas
performed using the Bonferroni method, where speciﬁed.
3. Results
3.1. Patterns of ER, PR and AR expression in EnOC
56.3% and 48.3% of cases demonstrated PR histoscore of 100
and200. For ER, 60.9% and 29.9% of cases displayed a histoscore of
100 and 200. 13.2% and 3.3% of cases demonstrated an AR his-
toscore of 100 and 200. Hormone receptor histoscores across
the EnOC cohort are summarised in Fig. S2 and Table S3. Expression
distribution was non-normal for all markers (Shapiro-Wilk
P< 0.001 for PR, ER and AR), and PR expression demonstrated a
bimodal distribution (Fig. S2A) (Hartigan's Dip test, P< 0.0001).
Expression of PR and ER demonstrated highly signiﬁcant cor-
relation (Spearman's r¼ 0.60, P< 0.0001). Expression of PR and ARFig. 1. Hierarchical clustering by PR, ER and ARdemonstrated weaker correlation that was also statistically signif-
icant (r¼ 0.34, P¼ 0.002), while ER and AR demonstrated signiﬁ-
cant correlation of intermediate magnitude (r¼ 0.45, P< 0.001).
3.2. PR/ER/AR-deﬁned subgroups of EnOC
84 cases had evaluable histoscores for all three markers (n¼ 15
not available [NA] for PR/ER/AR; n¼ 2 NA for ER/PR; n¼ 3 NA for
PR; n¼ 3 NA for ER). Hierarchical clustering of EnOC cases using
their PR, ER and AR histoscores identiﬁed subgroups of EnOC based
on hormone receptor expression patterns (Fig. 1). Four major sub-
groups were identiﬁed, deﬁned largely by patterns of PR and ER
expression: PRþ/ER (n¼ 21), PRþ/ERþ (n¼ 25), PR/ERþ
(n¼ 14) and PR/ER (n¼ 24).
AR expression appeared to contribute little toward subgroup
classiﬁcation, likely owing to the almost ubiquitous low expression
of AR across the cohort. However, AR histoscore was signiﬁcantly
lower in the PR/ER group versus the other EnOC groups (Bon-
ferroni-adjusted P< 0.01 for all comparisons) (Fig. S3, Table S4).
The PRhigh groups (PRþ/ERþ and PRþ/ER) demonstrated
favorable DSS (HR¼ 0.11, 95% CI 0.02e0.54 and 0.05, 95% CI
0.00e0.44, respectively) compared to the PR/ERþ group, with the
PR/ER group showing intermediate prognosis (HR¼ 0.50, 95% CI
0.18e1.40) (Fig. 2A and Table S5). These data were mirrored upon
investigation of RFS (Fig. 2B, Table S5). Within stage II cases specif-
ically, 10-year DSS in the PRhigh (n¼ 32) and PRlow cases (n¼ 15) was
94.1% and 42.4%, respectively (HR¼ 0.10, 95% CI 0.01e0.84) (Fig. S4).
3.3. Association of EnOC subgroups with clinicopathological
features in EnOC
Clinicopathological features of the four EnOC subgroups is sum-
marised in Table 2. The PRhigh groups (PRþ/ERþ and PRþ/ER)
appeared to comprise a greater portion EnOCs with grade I histology
(P¼ 0.023), early stage (FIGO I/II) at diagnosis (95.5% vs 81.6%,
P¼ 0.074) and wild-type p53 expression pattern (P¼ 0.042). How-
ever, these were not signiﬁcant following correction for multiple
testing (Bonferroni-adjusted P¼ 0.070, P¼ 0.222 and P¼ 0.127). The
PRþ/ER group appeared to demonstrate younger age at diagnosis,
but this did not reach statistical signiﬁcance (P¼ 0.055).
Due to the apparent differential distribution of clinicopatho-
logical features between the EnOC subgroups, a multivariable
analysis for DSS was performed to account for age, stage, grade and
residual disease following surgical debulking. In this model, the
PRhigh groups (PRþ/ERþ and PRþ/ER) demonstrated signiﬁcantly
favorable DSS (HR¼ 0.05, 95% CI 0.01e0.35 and 0.05, 95% CIhistoscores identiﬁes subgroups of EnOC.
Fig. 2. Disease-speciﬁc (A) and relapse-free (B) survival of EnOC subgroups.
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PR/ER group showing intermediate prognosis (HR¼ 0.24, 95% CI
0.06e0.99) (Tables S6 and S7).
3.4. Correlation of ER status in EnOC with body mass index at
patient presentation
We have previously reported a series of 265 HGS OC cases from
Edinburgh following contemporary pathology review [30]. The
EnOC cohort had higher BMI at ﬁrst-line chemotherapy initiation
compared to the HGS OC comparator cohort (median 25.5 vs 23.9,
P¼ 0.017) (Fig. 3). Within the EnOCs, ERhigh (PRþ/ERþ, PR/ERþ)
cases had a higher BMI compared to ERlow cases (median 27.6 vs
23.8, P¼ 0.015), whose BMI was akin to that of the HGS OC cohort
(median BMI 23.9, P¼ 0.8768). Accordingly, ERhigh EnOCs demon-
strated markedly higher BMI versus the HGS OC cases (P< 0.001;
Bonferroni-adjusted P¼ 0.002).
4. Discussion
There has been signiﬁcant research interest in the clinical
impact of hormone receptor expression in OC, with regard to both
patient survival [8e17,22] and sensitivity to endocrine therapy
[25e27]. Findings relating PR, ER and AR expression to clinical
outcome have been mixed, with studies typically performingTable 2
Demographics of EnOC subgroups.
Group
PRþ/ERþ
Age at diagnosis Median 59.0
BMI Median 27.2
Grade G1 EnOC 21 (84.0%)
G2 EnOc 2 (8.0%)
G3 EnOc 2 (8.0%)
FIGO stage at diagnosis I 11 (45.8%)
II 11 (45.8%)
III 2 (8.3%)
IV 0 (0.0%)
NA 1
RD following debulking <2 cm 22 (91.7%)
2 cm 2 (8.3%)
p53 IHC pattern AP 0 (0.0%)
AN 0 (0.0%)
WT 24 (100.0%)
NE 1
BMI, body mass index; EnOC, endometrioid ovarian carcinoma; NA, not available; RD, resi
aberrant null; WT, wild-type; NE, not evaluable.
a T test; PRþ/ER versus others.
b Mann Whitney-U test: ERhigh vs ERlow.
c c2 test, PRhigh (PRþ/ERþ and PRþ/ER) vs PRlow (PR/ERþ and PR/ER): low grad
d Fisher's exact test, PRhigh vs PRlow: early (FIGO I/II) vs advanced stage (FIGO III/IV).
e Fisher's exact test, PRhigh vs PRlow.
f Fisher's exact test, PRhigh vs PRlow: P53 aberrant vs wild-type pattern.analysis on heterogeneous OC cohorts without stratifying by his-
tological subtype of disease, which are now known to represent
distinct clinical and molecular disease entities [3]. Moreover,
methodologies for determining positivity have also been hetero-
geneous, with many studies classifying specimens only by the
proportion of positive tumor cells, without accounting for the in-
tensity of positive nuclear staining.
Here, we describe a cohort of EnOCs identiﬁed through
contemporary review of all available OCs diagnosed with endo-
metrioid histology at the Edinburgh Cancer Centre, utilizing IHC for
WT1 to improve the ﬁdelity of EnOC diagnosis. We assess positivity
for PR, ER and AR across 107 EnOCs e all of which were WT1
negative e using histoscore, a scoring method incorporating both
the percentage of positive nuclei and the intensity of nuclear
staining. Critically, we avoid sample classiﬁcation by arbitrarily
deﬁned positivity thresholds, instead performing clustering of
EnOCs based on their PR, ER and AR histoscores in order to identify
subgroups of disease deﬁned by patterns of hormone receptor
expression. EnOC specimens displayed a low frequency of AR pos-
itivity, and AR histoscore appeared to contribute little toward the
assignment of samples to the four identiﬁed subgroups.
EnOC cases demonstrating high levels of PR (PRþ/ERþ and PRþ/
ER groups) displayed markedly favorable clinical outcome. These
data are consistent with the prolonged survival described in EnOCsP-value
PRþ/ER PR/ERþ PR/ER
54.0 60.5 60.5 0.055a
23.4 28.9 24.1 0.015b
18 (85.7%) 7 (50.0%) 16 (66.7%) 0.023c
2 (9.5%) 5 (35.7%) 5 (20.8%)
1 (4.8%) 2 (14.3%) 3 (12.5%)
10 (50.0%) 6 (42.8%) 10 (41.7%) 0.074d
10 (50.0%) 6 (42.8%) 9 (37.5%)
0 (0.0%) 1 (7.1%) 3 (12.5%)
0 (0.0%) 1 (7.1%) 2 (8.3%)
1 0 0
20 (100.0%) 12 (92.3%) 21 (91.3%) 0.653e
0 (0.0%) 1 (7.7%) 2 (8.7%)
1 (4.8%) 3 (21.4%) 3 (13.0%) 0.042f
0 (0.0%) 0 (0.0%) 0 (0.0%)
20 (95.2%) 11 (78.6%) 20 (87.0%)
0 0 1
dual disease; IHC, immunohistochemistry; AP, aberrant diffuse nuclear positive; AN,
e (G1) versus high grade (G2/3).
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consortium [21], identifying 10-year patient survival of around 80%,
60e65% and 50% in those demonstrating 50%, 1e50% and <1% PR
positive tumor cell nuclei. The scoring method utilized in our study
e incorporating both percentage positive cells and the nuclear
staining intensity using histoscore emay have contributed toward
the identiﬁcation of a PRhigh EnOC population with exceptional 10-
year survival of >90% in this EnOC cohort, providing greater gran-
ularity for distinction of tumors demonstrating moderate or strong
marker positivity. While PR positivity appeared anti-correlated
with features associated with poor prognosis (advanced stage at
diagnosis, disease grade and patient age), multivariable analysis
identiﬁed PR as an independent factor associated with prognosis.
Perhaps most notably, PRhigh stage II cases demonstrated a 10-
year survival of approximately 95% compared to around 40% in the
corresponding PRlow cases. These data suggest that stage II EnOC
with high PR expression may be good candidates for de-escalation
of adjuvant chemotherapy regimens to endocrine therapy or
observation following primary surgical debulking.
For both PR and ER, the threshold for cluster separation during
subgroup identiﬁcation appeared to lie at a histoscore of approxi-
mately 150, and this histoscore threshold could readily be imple-
mented to routinely stratify EnOC management and improve
patient prognostication. We recently reported that HGS OCs with
strong ER positivity represent those that derive the greatest beneﬁt
from endocrine therapy [26], and similar investigations are now
warranted to better deﬁne the utility of endocrine therapies spe-
ciﬁcally in EnOC. Deﬁning the efﬁcacy of endocrine therapy in
PRhigh EnOC may further highlight potential opportunities to de-
escalate ﬁrst-line therapy for cases diagnosed with stage II disease.
A number of studies have suggested that ER-positive OCs
demonstrate favorable outcome compared to ER-negative cases
[9,11,13,15,16], including a large histotype-speciﬁc study of EnOC
[21]. We demonstrate highly signiﬁcant correlation between PR
and ER histoscore in our EnOC cohort, but did not identify a survival
beneﬁt in the PR/ERþ group. Together, these data suggest that
high ER expression may not be independently associated withFig. 3. Body mass index of EnOC versus high grade serous OC patients.better outcome in EnOC and that its association with PR expression
may explain the apparent survival advantage for ER-positive EnOC
patients upon univariable analysis. Indeed, in our cohort, the PR/
ERþ group demonstrated the least favorable outcome.
Upon investigation of BMI, the EnOC cohort appeared to
demonstrate higher BMI versus the HGS OC comparator cohort
from Edinburgh. However, upon closer investigation, ERhigh EnOCs
demonstrated signiﬁcantly higher BMI, while ERlow EnOCs were
comparable to HGS OCs. These data suggest that increased BMImay
be associated with development of ERhigh EnOC. Notably, higher
BMI is known to be associated with increased risk of endometrial
cancer, the majority of which display endometrioid histology and
are considered hormone-driven [31].
5. Conclusions
Together, these data add to the growing evidence that hormone
receptors represent clinically meaningful biomarkers of patient
outcome in OC. Optimal ﬁrst-line management strategies for pa-
tients with PRhigh EnOC e who appear to experience exceptional
long-term survivalemay nowwarrant re-evaluation, particularly in
the context of patients diagnosed with stage II disease who would
typically undergo systemic chemotherapy [32]. The relative efﬁcacy
of endocrine therapy in subgroups of EnOCs and other OC histotypes
should also be investigated following the recent demonstration of
greatest beneﬁt in HGS OCs demonstrating high ER expression [26].
Future studies should seek to deﬁne how expression levels of
hormone receptors e particularly PR and ER e overlap with other
molecularly-deﬁned subgroups of OC.Within HGS OCs, comparison
versus BRCA1/2mutation status may be of particular interest, given
the association of these events with improved clinical outcome and
sensitivity to DNA damaging agents and poly-(ADP-ribose) poly-
merase (PARP) inhibitors [33e35]. Indeed, there has already been
research interest in assessing such co-occurrence [21]. Critically,
these analyses will need to be performed in an OC histotype-
speciﬁc manner, owing to the distinct molecular landscape
demonstrate by each of these tumor types.
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